pentobarbital decreases effects of hemin by pharmacodynamic antagonism. Use Caution/Monitor. Prescription drugs that maximize delta-aminolevulinic acid synthetase may perhaps minimize hemin influence.
pentobarbital will lessen the extent or effect of roflumilast by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration not suggested; robust cytochrome P450 enzyme inducers decrease systemic exposure to roflumilast and may lessen the therapeutic performance
pentobarbital will lessen the extent or impact of siponimod by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Stay away from or Use Alternate Drug. Coadministration of siponimod having a drug that triggers moderate CYP2C9 in addition a average or potent CYP3A4 inducer just isn't recommended.
Keep an eye on Carefully (one)pentobarbital will lessen the extent or impact of linagliptin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch. Use of alternative treatment options is strongly proposed when linagliptin is to be administered having a CYP3A4 inducer
pentobarbital will decrease the extent or influence of isavuconazonium sulfate by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
Usually talk to your Health care service provider to ensure the information displayed on this webpage relates to your individual instances.
buprenorphine subdermal implant and pentobarbital equally raise sedation. Avoid or Use Alternate Drug. Limit use to clients for whom alternate therapy possibilities are insufficient
pentobarbital will lower the level or influence of amiodarone by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
pentobarbital will minimize the level or influence of temsirolimus by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
pentobarbital will minimize the extent or effect of saquinavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
Contraindicated (1)pentobarbital will reduce the extent or impact of doravirine by impacting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will decrease the extent or outcome of carbamazepine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.
Check Carefully (one)pentobarbital will decrease the level or influence of fentanyl transdermal by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Keep track of Carefully. Coadministration of fentanyl here with CYP3A4 inducers may lead to the decrease in fentanyl plasma concentrations, insufficient efficacy or, potentially, enhancement of the withdrawal syndrome inside a client who may have created physical dependence to fentanyl. Immediately after halting a CYP3A4 inducer, as the consequences from the inducer decline, the fentanyl plasma concentration will raise which could maximize or lengthen each the therapeutic and adverse outcomes.
pentobarbital will lower the extent or result of bosentan by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Mysterious.